Nanoparticle surface modification induced space charge suppression in linear low density polyethylene Appl. Phys. Lett. 95, 242905 (2009); 10.1063/1.3275732 Significant suppression of space charge injection into linear low density polyethylene by surface oxyfluorination

It is known that CH 3 NH 3 PbI 3 perovskite films with high crystallization and controlled morphology always show enhanced power conversion efficiency. Here we incorporate a small amount of polyvinylidene fluoride−trifluoroethylene polymer P(VDF-TrFE) into PbI 2 solution to control the crystallinity and morphology of perovskite layer in a two-step deposition process. Our results show that the P(VDF-TrFE) bridges the grain boundaries and also enhances the crystallinity of the perovskite layer significantly. By adjusting P(VDF-TrFE) concentration, the fabricated perovskite solar cells show improved average power conversion efficiency from 9.57 ± 0.25% to 12.54 ± 0.40% under a standard illumination of 100 milliwatts per square centimeter, which increases by nearly 31%. Thus, we demonstrate a new strategy to control the crystallinity and morphology of perovskite films by incorporating polymer into PbI 2 film in a two-step deposition process. In addition, this method has been proven as an effective way to prepare high-performance perovskite solar cells.

No abstract

No abstract

No abstract

For the first time, direct template-free electrodeposition of aligned NiZn nanofilaments was achieved on a tungsten substrate in a quiescent Lewis acidic ZnCl2-EMIC ionic liquid containing NiCl2 at 150 degrees C by applying an extremely large deposition overpotential.

DSE protected hepatocytes against APAP-induced injury via maintenance of mitochondrial metabolic activity, CYP2E1 inhibition, reduction of total glutathione depletion and preservation of redox status. Danshensu and Sal B were mainly responsible for this protection.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global crisis, urgently necessitating the development of safe, efficacious, convenient-to-store, and low-cost vaccine options. A major challenge is that the receptor-binding domain (RBD)-only vaccine fails to trigger long-lasting protective immunity if used alone for vaccination. To enhance antigen processing and cross-presentation in draining lymph nodes (DLNs), we developed an interferon (IFN)-armed RBD dimerized by an immunoglobulin fragment (I-R-F). I-R-F efficiently directs immunity against RBD to DLNs. A low dose of I-R-F induces not only high titers of long-lasting neutralizing antibodies (NAbs) but also more comprehensive T cell responses than RBD. Notably, I-R-F provides comprehensive protection in the form of a one-dose vaccine without an adjuvant. Our study shows that the pan-epitope modified human I-R-F (I-P-R-F) vaccine provides rapid and complete protection throughout the upper and lower respiratory tracts against a high-dose SARS-CoV-2 challenge in rhesus macaques. Based on these promising results, we have initiated a randomized, placebo-controlled, phase I/II trial of the human I-P-R-F vaccine (V-01) in 180 healthy adults, and the vaccine appears safe and elicits strong antiviral immune responses. Due to its potency and safety, this engineered vaccine may become a next-generation vaccine candidate in the global effort to overcome COVID-19.